Edition:
United States

Acasti Pharma Inc (ACST.OQ)

ACST.OQ on NASDAQ Stock Exchange Capital Market

1.60USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
75,086
52-wk High
$3.34
52-wk Low
$1.11

Chart for

About

Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 31.83 15.71
EPS (TTM): -- -- --
ROI: -- 15.03 31.93
ROE: -- 16.54 16.16

BRIEF-Acasti Pharma grants Chinese pharma co exclusive license to commercialize CaPre in China​

* Acasti Pharma Inc - ‍clarifies term of proposed strategic partnership with China pharmaceutical company​

Nov 22 2017

BRIEF-Acasti Pharma ‍enters into non-binding agreement with China-based pharma

* Acasti Pharma Inc - ‍entered into a non-binding term sheet with a China-based pharmaceutical company​

Nov 20 2017

BRIEF-Acasti Pharma says is offering 11.7 mln common shares‍​

* Says it is offering 11.7 million common shares‍​ - SEC Filing Source text: (http://bit.ly/2mBXlkS) Further company coverage:

Nov 16 2017

BRIEF-Acasti Pharma reports Q2 loss per share C‍$0.31​

* Acasti Pharma reports second quarter FY 2018 financial results

Nov 13 2017

BRIEF-Acasti Pharma files for offering of up to $17.25 mln of common stock‍​

* Acasti Pharma Inc files for offering of up to $17.25 million of common stock‍​ - sec filing‍​ Source text : http://bit.ly/2yN6Pf7 Further company coverage:

Sep 29 2017

BRIEF-Acasti Pharma reports Q1 loss per share c$0.19

* Acasti Pharma reports first quarter fy 2018 financial results

Aug 14 2017

BRIEF-Acasti Pharma issues common shares in payment of outstanding interest under debentures

* Acasti Pharma announces issuance of common shares in payment of outstanding interest under debentures Source text for Eikon: Further company coverage:

Jul 28 2017

Earnings vs. Estimates